Monash U Licenses IDBS’ E-Workbook
IDBS announced this week that the Centre for Drug Candidate Optimization at Australia’s Monash University, has licensed its E-WorkBook Suite to centralize the university’s research data.
As a collaborative research center within the Victorian College of Pharmacy at Monash University, the CDCO sought an application for the capture of both chemical and biological data generated by physiochemical and ADME studies of novel drug candidates, according to IDBS.
AstraZeneca to Evaluate Compendia Bioscience’s Oncomin
Compendia Bioscience has licensed Oncomine, a compendium of oncology gene expression profiles and analysis tools, to AstraZeneca, which will conduct a year-long pilot to evaluate the long-term role of this product in its cancer research programs.
This licensing agreement gives AstraZeneca access to Oncomine Concepts Edition, an extension of Oncomine that combines nearly 7,000 proprietary cancer gene signatures with 11,000 gene, protein, drug, and pathway signatures collected from the literature and other public sources, Compendia said in a statement.
The Concepts Map application uses gene sets as a common language to compare and link disparate biological concepts, allowing researchers to discover and explore new biology based on signatures related to drugs and/or disease pathways.
A study published in Nature Genetics (2007 Jan; 39(1): 41-51) used Oncomine Concepts Map to analyze prostate cancer gene expression in the context of the other gene signatures available in OCM. The result was an important new model describing the progression of prostate cancer, the company said.
Miraculins to use Diagnos Technology for Cancer Diagnostic Programs
Diagnos, which works on artificial intelligence and advanced knowledge extraction techniques, announced this week that its technology will be used by Miraculins in the development of its cancer diagnostic discovery programs.
Miraculins will pay Diagnos a consulting fee up to a maximum of $30,000 to review data and develop algorithms for its biomarkers discovery program, 50 percent of which will be paid in cash and 50 percent to be paid in shares of Miraculins issued once the work is completed.
Further details of the arrangement include that if Diagnos develops an algorithm for a diagnostic test that is used by Miraculins, Diagnos will receive a royalty of 5 percent of the actual gross commercial sales received by Miraculins per test, and in addition, Diagnos will also be granted 50,000 options, subject to regulatory approval.
Translational Genomics to Fuel Cancer Research Using SGI’s Altix
An SGI Altix 64-bit system has been employed by the Translational Genomics Research Institute (TGen) in order to aid the non-profit researchers in their cancer studies.
Researchers will use the system to study genomic variation between data sets, with the aim of one day better diagnosing and treating individual patients.
TNO Extends Toxicogenomics Licensing Agreement With GeneGo
GeneGo announced this week that TNO, the European Nutrigenomics Organisation Consortium and the Netherlands Nutrigenomics Consortium have extended their agreement with Genego. Further, the recently established Netherlands Toxicogenomics Center will soon acquire MetaCore and MetaDrug for applications in toxicogenomics.
This provides over 20 universities in Europe with access to MetaCore, the company said in a statement.